This study was conducted to see before and after treatment whether it provided improvement in the patient's clinical symptoms.
This research is the first to be conducted with preliminary research on humans.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
In the treatment group, standard therapy is given along with additional quercetin at different doses.
In the treatment group is give of Apple extract
Control Loratadine 10 mg/day
Universitas Sebelas Maret Hospital
Surakarta, Central Java, Indonesia
Total Nasal Symptom Score (TNSS)
The TNSS evaluates the severity of four nasal symptoms: nasal congestion, sneezing, nasal itching, and rhinorrhea. Each symptom is rated on a 4-point scale: 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total score is the sum of the four individual symptom scores, ranging from 0 to 12. Higher scores indicate worse symptom severity.
Time frame: Baseline, Month 3, and Month 6
Serum Interleukin-6 (IL-6) Levels
Concentration of IL-6 measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Time frame: Baseline, Month 3, and Month 6
Malondialdehyde (MDA) Levels
Oxidative stress marker measured using ELISA kit.
Time frame: Baseline, Month 3, and Month 6
Nuclear Factor-Kappa Beta (NF-kB) Expression
Transcription factor expression by ELISA assay.
Time frame: Baseline, Month 3, and Month 6
Serum Interleukin-8 (IL-8) Levels
Concentration of IL-6 measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Time frame: Baseline, Month 3, and Month 6
Serum TNF-alpha Levels
Concentration of TNF-alpha measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Time frame: Baseline, Month 3, and Month 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Control Fluticasone Furoate 27.5 mcg twice daily